Search

Your search keyword '"Yang, Chunmei"' showing total 10 results
Start Over Author "Yang, Chunmei" Journal blood
10 results on '"Yang, Chunmei"'

1. The ZR2-Minichop Study：Zanubrutinib, Lenalidomide, Rituximab, Cyclophosphamide, Vincristine, Epirubicin and Prednisone in Elderly Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Author

Sun, Jianai, primary, Xu, Yi, additional, Yang, Min, additional, Wang, Huafeng, additional, Yu, Wenjuan, additional, You, Liangshun, additional, Meng, Haitao, additional, Yang, Chunmei, additional, Zhou, Xinping, additional, Li, Li, additional, Zhou, De, additional, Ye, Xiujing, additional, Zhu, Hong-hu, additional, Tong, Hongyan, additional, Jin, Jie, additional, and Xie, Wanzhuo, additional

Published
2022
Full Text
View/download PDF

3. Safety and Feasibility of Anti-CD19 CAR-T Expressing IL-7 and CCL19 in Patients with Relapsed or Refractory Large B-Cell Lymphoma

Author

Lei, Wen, primary, Ai, Zhao, additional, Liu, Hui, additional, Yang, Chunmei, additional, Wei, Cheng, additional, Guo, Shanshan, additional, Chen, Zhilu, additional, Guo, Qunyi, additional, Li, Linjie, additional, Zhao, Mingzhe, additional, Wu, Gongqiang, additional, Zhang, Jinyi, additional, Gao, Jimin, additional, and Qian, Wenbin, additional

Published
2022
Full Text
View/download PDF

4. Novel Sirpα-Fc Fusion Protein IMM01 Exhibits Dual Anti-Tumor Activities By Targeting CD47/Sirpα Signal Pathway

Author

Yu, Jifeng, primary, Li, Song, additional, Chen, Dianze, additional, Liu, Dandan, additional, Guo, Huiqin, additional, Yang, Chunmei, additional, Zhang, Wei, additional, Zhang, Li, additional, Zhao, Gui, additional, Tu, Xiaoping, additional, Peng, Liang, additional, Liu, Sijin, additional, Bai, Xing, additional, Song, Yongping, additional, Jiang, Zhongxing, additional, Zhang, Ruliang, additional, and Tian, Wenzhi, additional

Published
2022
Full Text
View/download PDF

6. Small-Dose Trimethoprim-Sulfamethoxazole Prevents Pneumocystis Jiroveci Pneumonia in B-Cell Lymphoma Patients Receiving Chemotherapy: Analysis of a Randomized Controlled Clinical Trial

Author

Liu, Chunxiao, Zhang, Xuewu, Zhu, Yanan, Xiao, Feng, Lv, Yunfei, Ye, Xingnong, Li, Xia, Wei, Juying, Wang, Huafeng, Zhou, Yile, Tong, Hongyan, Zhou, Xinping, Yang, Chunmei, Mao, Liping, Zhou, De, Zhu, Li, Zheng, Xiaolong, Ye, Li, You, Liangshun, Jin, Jie, and Yu, Wenjuan

Abstract

B-cell lymphoma is the most common non-Hodgkin lymphoma and is usually treated with the R-CHOP regimen. However, some patients might develop interstitial pneumonitis (IP), which has led to death in some patients. With advances in detection techniques, infections are now considered to be an important etiologic factor in IP, particularly the common opportunistic causative agent Pneumocystis jiroveci. A retrospective cohort analysis at our center has tentatively elucidated that TMP-SMX can achieve effective IP prevention. There are no prospective studies to confirm the preventive effect of TMP-SMX and its mechanism.

Published
2023
Full Text
View/download PDF

8. Humanized Monoclonal Antibody IMM47, Targeting CD24, Exhibits Exceptional Anti-Tumor Efficacy By Blocking the CD24/Siglec-10 Interaction and Can be Used As Monotherapy or in Combination with Anti-PD1 Antibodies for Cancer Immunotherapy

Author

Yu, Jifeng, Li, Song, Chen, Dianze, Guo, Huiqin, Yang, Yanan, Liu, Dandan, Yang, Chunmei, Bai, Xing, Zhang, Wei, Zhang, Li, Zhao, Gui, Tu, Xiaoping, Peng, Liang, Liu, Sijin, Song, Yongping, Jiang, Zhongxing, Zhang, Ruliang, and Tian, Wenzhi

Abstract

Background:

Published
2023
Full Text
View/download PDF

9. Risk Factors for Severe Infection and Unfavorable Outcomes in Hematologic Malignancy Patients with COVID-19 Inflection during the Omicron Era: A Chinese Single-Center Retrospective Study

Author

Ye, Li, Yang, Ye, Zhang, Xuewu, Wang, Lu, Zhu, Li, Li, Xia, Zhou, Yile, Zheng, Xiaolong, Zhou, Xinping, Ren, Yanling, Ma, Liya, Xu, Gaixiang, Yang, Chunmei, Wang, Huafeng, Zhou, De, Yang, Min, Ye, Xingnong, Wei, Juying, Yu, Wen-Juan, Qian, Jiejing, Lou, Yinjun, Xie, Wanzhuo, Huang, Jian, Meng, Haitao, Jin, Jie, and Tong, Hongyan

Abstract

Purpose: The objective of this study was to evaluate the potential risk factors associated with severe infection and unfavorable outcomes among individuals with hematologic malignancies who contracted the coronavirus infectious disease (COVID-19) during the Omicron era.

Published
2023
Full Text
View/download PDF

10. Safety and Efficacy of Selinexor Sequential Azacytidine in Newly Diagnosed Patients with Myelodysplastic Syndromes EB1 or EB2: A Single-Center, Single-Arm, Phase Ib/II Trial

Author

Ma, Liya, Yang, Wenli, Zhou, Xinping, Ye, Li, Xu, Gaixiang, Hu, Chao, Luo, Yingwan, Yang, Chunmei, Ge, Zheng, and Tong, Hongyan

Abstract

Background:Azacytidine is one of the hypomethylating agents (HMAs) for the treatment of higher-risk myelodysplastic syndromes (MDS). However, clinical outcomes of patients treated with azacytidine monotherapy were far from satisfactory with overall response rate (ORR) of 41%-59% and overall survival (OS) of 15-18 months. Selinexor is an oral, first-in-class selective inhibitor of nuclear export compound that inhibits exportin 1 (XPO1). Preclinical studies have shown that inhibition of XPO1 causes nuclear accumulation of p53 and disruption of NF-κB signaling, both relevant targets for myelodysplastic syndromes. Prior study reported an ORR of 26% and mOS of 8.7 months with selinexor in HMAs-refractory MDS patients. We therefore aimed to assess the safety and efficacy of selinexor sequential azacytidine in newly diagnosed patients with MDS-EB1 or EB2.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results